Aardvark Therapeutics is headquartered at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122.
Aardvark Therapeutics was incorporated in May 2017 in Delaware.
Aardvark Therapeutics’ common stock began trading on the Nasdaq Global Market under the ticker symbol AARD on February 13, 2025.
Aardvark Therapeutics’ fiscal year is from January 1st to December 31st.
Aardvark Therapeutics’ transfer agent is Equiniti Trust Company, LLC
For inquiries regarding transfer requirements, lost certificates, changes of address, or other matters related to share ownership, please contact:
By Mail, Overnight Courier or Hand-Delivery to:
Equiniti Trust Company, LLC
48 Wall Street, Floor 23
New York, NY 10005
By Phone or Email:
Telephone: (800) 937-5449
Outside the U.S., Canada and Puerto Rico: +1 (718) 921-8137
Email: help@astfinancial.com
Aardvark Therapeutics’ independent auditor is BDO USA, P.C.
Aardvark Therapeutics’ legal counsel is Paul Hastings LLP.
Corporate news can be found in the News & Events section of our Investor Relations webpage. Quarterly and annual reports and other SEC filings can be found in the Financials section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
Aardvark Therapeutics’ financial documents can be found in the Financials section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
Please email investorrelations@aardvarktherapeutics.com.
Alerts can be set up from the Email Alerts section of the IR Resources tab.
Aardvark Therapeutics does not currently have a direct stock purchase plan.
Please see the Management Team and Board of Directors sections under the Governance tab of our Investor Relations webpage.
Please see aardvarktherapeutics.com.